Mutual helper effect in copulsing of dendritic cells with 2 antigens: A novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously

Journal of Immunotherapy

Volumn 32, Issue 4, 2009, Pages 325-332

  Shojaeian, Jaleh ^a   Jeddi Tehrani, Mahmood ^b,c   Dokouhaki, Pouneh ^a   Mahmoudi, Ahmad Reza ^d   Ghods, Roya ^d   Bozorgmehr, Mahmood ^e   Nikoo, Shohreh ^e   Bayat, Ali Ahmad ^b   Akhondi, Mohammad Mehdi ^f   Ostadkarampour, Mahyar ^b   Rezania, Simin ^g   Zarnani, Amir Hassan ^a,h,i  

^a Departments of Reproductive Immunology   (Sweden)

^b Departments of Hybridoma   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

^e TARBIAT MODARES UNIVERSITY   (Iran)

^f Reproductive Biotechnology Research Center   (Iran)

^g IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ SHAHID BEHESHTI UNIVERSITY   (Iran)

Author keywords

Antigen pulsing; Dendritic cells; Helper protein; Immunotherapy; Tumor

Indexed keywords

ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; MYCOBACTERIUM ANTIGEN; MYOGLOBIN; OVALBUMIN; OVOTRANSFERRIN; PROSTATE SPECIFIC ANTIGEN; THREONYLPHENYLALANYLLEUCYLTHREONYLSERYLGLUTAMYLLEUCYLPROLYLGLYCYLTRYPTOPHYLLEUCYLGLUTAMINYLALANYLASPARAGINYLARGINYLHISTIDYLVALYLLYSYLPROLYLTHREONINE; UNCLASSIFIED DRUG; CANCER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COMMUNICABLE DISEASE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPH NODE; LYMPHOCYTE ACTIVATION; NEOPLASM; TRANSPLANTATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMMUNICABLE DISEASES; DENDRITIC CELLS; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS;

EID: 67449087551     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31819aa31e     Document Type: Article

References (47)

1. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997;9:10-16.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
3. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18:767-811.
4. Ni K, O'Neill HC. The role of dendritic cells in T cell activation. Immunol Cell Biol. 1997;75:223-230.
5. Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science. 2001;293:253-256.
6. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245-273.
7. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med. 2001;7:761-765.
8. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer. 2001; 94:459-473.
9. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest. 2002;109:1519-1526.
10. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol. 2000; 12: 114-121.
11. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother. 2002;25:289-303.
12. Moll H, Berberich C. Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis. Immunobiology. 2001;204:659-666.
13. Markiewicz MA, Kast WM. Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest. 2004;22:417-434.
14. Yu Z, Restifo NP. Cancer vaccines: progress reveals new complexities. J Clin Invest. 2002;110:289-294.
15. Aragoneses-Fenoll L, Corbi AL. Dendritic cells: still a promising tool for cancer immunotherapy. Clin Transl Oncol. 2007;9:77-82.
16. Saito H, Frleta D, Dubsky P, et al. Dendritic cell-based vaccination against cancer. Hematol Oncol Clin North Am. 2006;20:689-710.
17. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
18. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
19. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
20. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood. 1999;93:2411-2419.
21. Holtl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999;161:777-782.
22. Salgaller ML, Thurnher M, Bartsch G, et al. Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials. Cancer. 1999;86:2674-2683.
23. Strome SE, Voss S, Wilcox R, et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 2002;62:1884-1889.
24. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001;61:8105-8109.
25. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL crosspriming. Nat Med. 2001;7:297-303.
26. Yamanaka R, Zullo SA, Ramsey J, et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg. 2002;97:611-618.
27. Wang J, Saffold S, Cao X, et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol. 1998;161: 5516-5524.
28. Osada T, Clay TM, Woo CW, et al. Dendritic cell-based immunotherapy. Int Rev Immunol. 2006;25:377-413.
29. Zarnani AH, Moazzeni SM, Shokri F, et al. The efficient isolation of murine splenic dendritic cells and their cytochemical features. Histochem Cell Biol. 2006;126:275-282.
30. Shojaeian J, Moazzeni SM, Nikoo SH, et al. Immunosuppressive effect of pregnant mouse serum on allostimulatory activity of dendritic cells. J Reprod Immunol. 2007;75:23-31.
31. Zarnani AH, Moazzeni SM, Shokri F, et al. Microenvironment of the feto-maternal interface protects the semiallogenic fetus through its immunomodulatory activity on dendritic cells. Fertil steril. 2008;90:781-788.
32. + tumor-infiltrating lymphocytes. J Exp Med. 1991;173:647-658.
33. Shimizu K, Thomas EK, Giedlin M, et al. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 2001;61: 2618-2624.
34. + T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines. Vaccine. 2003;21: 869-876.
35. Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol. 2000;164:4797-4803.
36. Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysatepulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 2001;61:6445-6450.
37. Casares N, Lasarte JJ, de Cerio AL, et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol. 2001;31:1780-1789.
38. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev. 2002;188:97-113.
39. Tomlinson IP, Novelli MR, Bodmer WF. The mutation rate and cancer. Proc Natl Acad Sci USA. 1996;93:14800-14803.
40. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996; 184:747-755.
41. Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol. 1999;11: 76-81.
42. Giacomini P, Fisher PB, Duigou GJ, et al. Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon [review]. Anticancer Res. 1988;8:1153-1161.
43. Melief CJ, Toes RE, Medema JP, et al. Strategies for immunotherapy of cancer. Adv Immunol. 2000;75:235-282.
44. + T cell responses in antitumor immunity. Curr Opin Immunol. 1998; 10: 588-594.
45. Toes RE, Ossendorp F, Offringa R, et al. CD4 T cells and their role in antitumor immune responses. J Exp Med. 1999; 189: 753-756.
46. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med. 1998;188:2199-2204.
47. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNg receptor expression by nonhematopoietic cells. Immunity. 2000;12:677-686.